# OnCo record iovance (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/iovance/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "iovance" ;
  schema:name "Iovance Biotherapeutics"@en ;
  schema:description "Iovance Biotherapeutics, of San Carlos, California, makes Amtagvi (lifileucel), the first approved tumour-infiltrating lymphocyte therapy, a treatment grown from a patient's own tumour-resident immune cells and approved in melanoma. Making it fast and cheap enough to reach most eligible patients is its open question."@en ;
  schema:url <https://onco.cc/companies/iovance/>, <https://www.iovance.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Iovance_Biotherapeutics> ;
  owl:sameAs <http://www.wikidata.org/entity/Q85769888> ;
  schema:citation <https://www.iovance.com> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:drugs <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/aldesleukin/> ;
  onco:trials <https://onco.cc/trials/nct05727904/>, <https://onco.cc/trials/nct07288203/>, <https://onco.cc/trials/nct06481592/>, <https://onco.cc/trials/nct06940739/>, <https://onco.cc/trials/nct04614103/>, <https://onco.cc/trials/nct05361174/> .